Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 264

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Phase II Study of High-Dose Photon/Proton Radiotherapy in the Management of Spine Sarcomas

Open access
DeLaney, Thomas F., Liebsch, Norbert J., Pedlow, Francis X., Adams, Judith, Dean, Susan, Yeap, Beow Y., McManus, Patricia, Rosenberg, Andrew E., Nielsen, G. Petur, Harmon, David C., Spiro, Ira J., Raskin, Kevin A., Suit, Herman D., Yoon, Sam S., Hornicek, Francis J. · 2009 · International Journal of Radiation Oncology*Biology*Physics

Abstract

Purpose Radiotherapy (XRT) for spine sarcomas is constrained by spinal cord, nerve, and viscera tolerance. Negative surgical margins are uncommon; hence, doses of ≥ 66 Gy are recommended. A Phase II clinical trial evaluated high dose photon/proton XRT for spine sarcomas. Materials/Methods Eligible patients had non-metastatic, thoracic, lumbar, and/or sacral spine/paraspinal sarcomas. Treatment included pre- and/or post-op photon/proton XRT +/- radical resection; patients with osteosarcoma and Ewing's sarcoma received chemotherapy. Shrinking fields delivered 50.4 cobalt Gray equivalent (GyRBE) to subclinical disease, 70.2 GyRBE to microscopic disease in the tumor bed, and 77.4 GyRBE to gross disease at 1.8 GyRBE q.d. Doses were reduced for radiosensitive histologies, concurrent chemoradiation, or when diabetes or autoimmune disease present. Spinal cord dose was limited to 63/54 GyRBE to surface/center. Intra-operative boost doses of 7.5-10 Gy could be given by dural plaque. Results 50 patients (29 chordoma, 14 chondrosarcoma, 7 other) underwent gross total (n=25) or subtotal (n=12) resection or biopsy (n=13). With 48 month median follow-up, five-year actuarial local control, recurrence-free survival, and overall survival are: 78%, 63%, and 87% respectively. Two of 36 (5.6%) patients treated for primary versus 7/14 (50%) for recurrent tumor developed local recurrence, p<0.001. Five patients developed late radiation-associated complications; no myelopathy developed but three sacral neuropathies appeared following 77.12-77.4 GyRBE. Conclusions Local control with this treatment is high in patients radiated at the time of primary presentation. Spinal cord dose constraints appear to be safe. Sacral nerves receiving 77.12-77.4 GyRBE are at risk for late toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2008.08.058

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 264

Metadata

Authors
DeLaney, T. F., Liebsch, N. J., Pedlow, F. X., Adams, J., Dean, S., Yeap, B. Y., McManus, P., Rosenberg, A. E., Nielsen, G. P., Harmon, D. C., Spiro, I. J., Raskin, K. A., Suit, H. D., Yoon, S. S., & Hornicek, F. J.
Venue
International Journal of Radiation Oncology*Biology*Physics
Publisher
Elsevier BV
Published
2009-07
Volume
74
Issue
3
Pages
732-739
ISSN
0360-3016 (ISSN-L)
OpenAlex
W1971742491
Cited by
264
References
10
FWCI
11.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of High-Dose Photon/Proton Radiotherapy in the Management of Spine Sarcomas. https://app.cochat.ai/papers/10.1016/j.ijrobp.2008.08.058
The paper
DeLaney, T. F., Liebsch, N. J., Pedlow, F. X., Adams, J., Dean, S., Yeap, B. Y., McManus, P., Rosenberg, A. E., Nielsen, G. P., Harmon, D. C., Spiro, I. J., Raskin, K. A., Suit, H. D., Yoon, S. S., & Hornicek, F. J. (2009). Phase II Study of High-Dose Photon/Proton Radiotherapy in the Management of Spine Sarcomas. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2008.08.058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.